Showing 691-700 of 7446 results for "".
Access Is Everything
https://practicaldermatology.com/topics/practice-management/access-is-everything/23942/The Safe Step Act of 2023 seeks to rein in fail-first policies and protect patients.DermWireTV: ASDS Meeting Highlights; Daxxify Data; PA Week
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-asds-meeting-highlights-daxxify-data-pa-week/20147/ASDS speakers address aesthetic advancements, skin cancer, and DEI with Joel L. Cohen, MD, Sherrif Ibrahim, MD, and Jeanine Downie, MD. On the heels of FDA approval of Revance’s Daxxify, data published in the Aesthetic Surgery Journal demonstrate the efficacy of DaxibotulinumtoxinA for patients of dScientifically Speaking: New Directions in Acne Management, Part 2
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-new-directions-in-acne-management-part-2/19950/From the optimal, safe use of isotretinoin to the proper role for systemic antibiotics and beyond, there are multiple areas of systemic acne care that deserve attention. In the second of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, MD; Linda Stein Gold, MD; and Emil Tanghetti, MD aCheckpoint Blockade for Advanced cSCC: Exploring Newer Options
https://practicaldermatology.com/topics/skin-cancer-photoprotection/checkpoint-blockade-for-advanced-cscc-exploring-newer-options/23487/Two newer systemic options on the market provide hope in the fight against advanced cutaneous squamous cell carcinoma.DermWireTV: AAD's Diversity Plan, Galderma Acne Data, Nutrafol Pro-Strength Boosters
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-aads-diversity-plan-galderma-acne-data-nutrafol-pro-strength-boosters/19903/Kanya Ferguson, MD, FAAD, Chair of the AAD’s Diversity Committee, speaks about the AAD’s new comprehensive, three-year plan focused on Diversity, Equity, and Inclusion. It was approved with unanimous support by the AAD’s Board of Directors. A new survey conducted by Galderma and retinoid brand AklieFrax Pro and CoolSculpting Elite Launch, Antibiotic Resistance in Rosacea, Thriving in Aesthetics Rolls Out
https://practicaldermatology.com/series/dermwire-tv/frax-pro-and-coolsculpting-elite-launch-antibiotic-resistance-in-rosacea-thriving-in-aesthetics-rolls-out/19896/The majority of rosacea patients have never heard of antibiotic resistance, a new survey reported by the National Rosacea Society finds. Candela’s Frax Pro system is now available, featuring Frax 1550 and the novel Frax 1940 applicators. Allergan Aesthetics, an AbbVie company, is launching CoolSculpManagement of Atopic Dermatitis During the COVID-19 Pandemic
https://practicaldermatology.com/topics/atopic-dermatitis/management-of-atopic-dermatitis-during-the-covid-19-pandemic/23322/There is concern about the immunosuppressive or immunomodulatory effects of oral and biologic medications in patients with skin disease.DermWireTV: AAD Virtual Data Highlights, Cynosure Consumer Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-aad-virtual-data-highlights-cynosure-consumer-data/19818/The American Academy of Dermatology 2020 VMX Virtual Conference shines a light on fresh data from UCB, Leo Pharma, Lilly and Dermira, and Soliton. Cassiopea reports long-term data for Clascoterone. Zilxi from Menlo and Foamix approved for rosacea. Cynosure reports positive cosmetic consumer outlookNewly Approved Therapies for the Treatment of Plaque Psoriasis in Adults
https://practicaldermatology.com/topics/psoriasis/newly-approved-therapies-for-the-treatment-of-plaque-psoriasis-in-adults/23213/Here’s a closer a look at recently approved agents.DermWireTV: Allē Launches; Arazlo Cleared; BTL Files Suit
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-alle-launches-arazlo-cleared-btl-files-suit/19714/More than 10 Years and 6 million members later, the Brilliant Distinctions program is being relaunched with a new name and a new app: Allē. Arazlo Lotion 0.045%, the first lotion formulation of tazarotene, is now FDA approved for the topical treatment of acne vulgaris in patients nine years of age a